Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy

Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy

Abstract Crizotinib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity against mesenchymal-epithelial transition factor (MET) and anaplastic lymphoma kinase (ALK). However, the concomitant oncogenic drivers may affect the sensitivity of crizotinib. Herein, we present a 69-year-old nev...

Full description

Bibliographic Details
Main Authors: Fei-fei Gu, Yong Zhang, Yang-yang Liu, Xiao-hua Hong, Jin-yan Liang, Fan Tong, Jing-song Yang, Li Liu
Format: Article
Language:English
Published: BMC 2016-08-01
Series:Journal of Hematology & Oncology
Subjects:
NSCLC
Lung adenocarcinoma
Oncogenic drivers
SPTBN1-ALK
c-Met
HER-2
Online Access:http://link.springer.com/article/10.1186/s13045-016-0296-8

Internet

http://link.springer.com/article/10.1186/s13045-016-0296-8

Similar Items